CASP3 and thyroid cancer: Another study showed that the dual inhibition of PI3K/HDAC by 24 h of CUDC-907 treatment can activate the apoptosis pathway in thyroid cancer cell lines by significantly increasing the activity of caspase 3/7 [29].